After falling as much as 14% in the early session, ImmunoTherapeutics Inc (NYSEAMERICAN:BTX) stock has recovered very well and now turned green on heavy volume. At the time of writing, BTX stock is trading higher by 4.62% at $35.80 after hitting a session low of $29.41.
The stock has been on a roll this month as the stock went up as much as 1350% till April 28th, when it made a new high of $54.24. However, since then the stock fell almost 45% in the next two trading sessions.
Earlier this week, the company announced had acquired an exclusive license for mRNA gene editing and cell therapies technology of Factor Bioscience Limited and Novellus Therapeutics Limited pursuant to an exercise of a previously announced option.
The license includes the use of an extensively patented process to develop gene-editing compounds using mRNA, which preclinical data suggest demonstrate a high degree of efficiency, as well as being non-immunogenic and non-mutagenic.
BTX stock is a very volatile stock and carries immense risk considering the huge rally. So keep an eye on BTX stock.
Editor and Computer Expert
A hardcore tech enthusiast and computer expert Uson Abdilazhanov who holds a degree in communications started writing in his personal blogs since 2012. That time he was interested in the technical part of the computer. But now the software aspect plays an important role in his career. Currently, he runs a PC building and repairing shop which helps a lot of designers and gamers who always like to try new things.